Tompkins Financial Corp Buys 232 Shares of Amgen Inc. (NASDAQ:AMGN)

Tompkins Financial Corp lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,411 shares of the medical research company’s stock after acquiring an additional 232 shares during the period. Tompkins Financial Corp’s holdings in Amgen were worth $10,443,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. AIA Group Ltd acquired a new position in shares of Amgen during the 1st quarter worth about $612,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Amgen during the 1st quarter worth approximately $2,957,000. Montag A & Associates Inc. raised its stake in shares of Amgen by 84.8% during the 1st quarter. Montag A & Associates Inc. now owns 5,775 shares of the medical research company’s stock worth $1,642,000 after purchasing an additional 2,650 shares in the last quarter. Atomi Financial Group Inc. grew its stake in shares of Amgen by 115.1% in the first quarter. Atomi Financial Group Inc. now owns 3,736 shares of the medical research company’s stock valued at $1,062,000 after buying an additional 1,999 shares in the last quarter. Finally, Chilton Capital Management LLC grew its stake in shares of Amgen by 5.9% in the first quarter. Chilton Capital Management LLC now owns 67,615 shares of the medical research company’s stock valued at $19,224,000 after buying an additional 3,773 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ:AMGN traded up $3.37 during trading on Friday, hitting $325.28. 1,978,146 shares of the company were exchanged, compared to its average volume of 2,410,161. Amgen Inc. has a 1-year low of $260.52 and a 1-year high of $346.85. The company has a market capitalization of $174.85 billion, a P/E ratio of 41.65, a price-to-earnings-growth ratio of 2.79 and a beta of 0.60. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The business’s 50 day moving average is $323.61 and its 200-day moving average is $317.08.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period last year, the company earned $4.96 EPS. Equities analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.77%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AMGN. Barclays increased their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $305.00 target price (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. Robert W. Baird restated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price (up previously from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $333.50.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.